

603421

FORM 1

SPRUSON & FERGUSON

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

APPLICATION FOR A STANDARD PATENT

Tanabe Seiyaku Co., Ltd., of No. ^{2-10.} ~~21~~ Doshomachi 3-chome, ~~Osaka-shi~~ ^{Chuo-ku,} ~~Higashi-ku,~~ Osaka, JAPAN, hereby apply for the grant of a standard patent for an invention entitled:

Agent having Renal function-improving effect and Diuretic effect

which is described in the accompanying complete specification.

Details of basic application(s):-

<u>Basic Applic. No:</u>	<u>Country:</u>	<u>Application Date:</u>
29396/1987	JAPAN	10 February 1987

The address for service is:-

Spruson & Ferguson
Patent Attorneys
Level 33 St Martins Tower
31 Market Street
Sydney New South Wales Australia

FEE STAMP TO VALUE OF
\$ 190.00 ATTACHED
MAIL OFFICER

DATED this NINTH day of FEBRUARY 1988

Tanabe Seiyaku Co., Ltd.

By: *N.J. Anderson*

Registered Patent Attorney


TO: THE COMMISSIONER OF PATENTS
OUR REF: 49393
S&F CODE: 64290

LODGED AT SUB-OFFICE
- 9 FEB 1988
Sydney

5845/4

COMMUNICATION ACCEPTED AND AMENDMENTS

RECEIVED 24-8-90



DECLARATION IN SUPPORT OF A
CONVENTION APPLICATION FOR A PATENT

In support of the Convention Application made for a
patent for an invention entitled:

Title of Invention

Agent having Renal function-improving effect and
Diuretic effect

Full name(s) and
address(es) of
Declarant(s)

I/We Keijiro Adachi, President & Representative Director

of Tanabe Seiyaku Co., Ltd.
No. 21, Dosho-machi 3-chome,
Higashi-Ku, Osaka-shi, Osaka-fu,
Japan

do solemnly and sincerely declare as follows:-

Full name(s) of
Applicant(s)

1. I am/We are the applicant(s) for the patent
(or, in the case of an application by a body corporate)
1. I am/We are authorised by
Tanabe Seiyaku Co., Ltd.
the applicant(s) for the patent to make this declaration on
its/their behalf.
2. The basic application(s) as defined by Section 141 of the
Act was/were made

Basic Country(ies)

in Japan

Priority Date(s)

on 10 February, 1987

Basic Applicant(s)

by Tanabe Seiyaku Co., Ltd.

Full name(s) and
address(es) of
inventor(s)

3. I am/We are the actual inventor(s) of the invention referred
to in the basic application(s)
(or where a person other than the inventor is the applicant)

3. ISAO YAMAGUCHI, YOSHIAKI AKIMOTO and TAKU NAGAO

of No. 3-16-8, Ogikubo, Suginami-ku, Tokyo-to, Japan;
No. 3-19-3-204, Asahi, Kawaguchi-shi, Saitama-ken,
Japan and No. 4-36-21, Kamimeguro, Meguro-ku, Tokyo-to,
Japan (respectively)

is/are the actual inventor(s) of the invention and the facts upon
which the applicant(s) is/are entitled to make the application are
as follows:

Set out how Applicant(s)
derivative from actual
inventor(s) e.g. The
Applicant(s) is/are the
assignee(s) of the
invention from the
inventor(s)

The said applicant is the assignee of the
actual inventors.

4. The basic application(s) referred to in paragraph 2 of this
Declaration was/were the first application(s) made in a Convention
country in respect of the invention(s) the subject of the application.

Declared at Osaka-shi this
Japan

25 day of January, 1988
Tanabe Seiyaku Co., Ltd.

(12) PATENT ABRIDGMENT (11) Document No. AU-B-11466/88
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 603421

(54) Title
A PHARMACEUTICAL COMPOSITION OF
2-(4-METHOXYPHENYL)-3-ACETOXY-5-(2-DIMETHYL
AMINO)ETHYL)-8-CHLORO-2,3-DIHYDRO -1,5-BENZOTHAZEPIN-4(5H)-ONE

International Patent Classification(s)
(51)^a A61K 031/55

(21) Application No. : 11466/88

(22) Application Date : 09.02.88

(30) Priority Data

(31) Number (32) Date (33) Country
62-29396 10.02.87 JP JAPAN

(43) Publication Date : 11.08.88

(44) Publication Date of Accepted Application : 15.11.90

(71) Applicant(s)
TANABE SEIYAKU CO., LTD.

(72) Inventor(s)
ISAO YAMAGUCHI; TAKU NAGAO; YOSHIKI AKIMOTO

(74) Attorney or Agent
SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001

(56) Prior Art Documents
GB 2154577
GB 2154578
US 4822789

(57) Claim

1. A method for the treatment or prophylaxis of renal failure or edema in a patient requiring said treatment or prophylaxis, which method comprises administering to said patient an effective renal function improving or diuresis inducing amount of a formulation which comprises as an active ingredient 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)-ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4-(5H)-one or a pharmaceutically acceptable acid addition salt thereof in admixture with a pharmaceutically acceptable carrier.

5. A method according to any one of claims 1 to 4 wherein the renal failure is acute or chronic renal failure resulting from glomerulonephritis, nephrotic syndrome, nephrosclerosis, tubular disorder or ischemic renal failure.

603421

S & F Ref: 49393

FORM 10

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

COMPLETE SPECIFICATION

(ORIGINAL)

FOR OFFICE USE:

Class Int Class

Complete Specification Lodged:
Accepted:
Published:

Priority:

Related Art:

This document contains the amendments made under Section 49 and is correct for printing.

Name and Address
of Applicant:

Tanabe Seiyaku Co., Ltd.
2-10, Doshomachi 3-chome
Chuo-ku,
Osaka
JAPAN

Address for Service:

Spruson & Ferguson, Patent Attorneys
Level 33 St Martins Tower, 31 Market Street
Sydney, New South Wales, 2000, Australia

Complete Specification for the invention entitled:

Agent having Renal function-improving effect and Diuretic effect

The following statement is a full description of this invention, including the best method of performing it known to me/us




Abstract:

Agent having renal function-improving effect and diuretic effect

5

Disclosed are an agent having a renal function-improving effect and a diuretic effect comprising as an active ingredient 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one or a pharmaceutically acceptable acid addition salt thereof, and use of the same for preparing an agent having a renal function-improving effect and a diuretic effect.

10



Agent having renal function-improving effect and diuretic effect

BACKGROUND OF THE INVENTION

The present invention relates to a novel agent having a renal function-improving effect and a diuretic effect.

5 It has been known that 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one or a pharmaceutically acceptable acid addition salt thereof has excellent hypotensive activity and cerebral or coronary vasodilating activity (Japanese Unexamined Patent Publication No. 225174/1984).

10 SUMMARY OF THE INVENTION

According to a broad from of the present invention there is provided a method for the treatment or prophylaxis of renal failure or edema in a patient requiring said treatment or prophylaxis, which method comprises administering to said patient an effective renal function improving or diuresis inducing amount of a formulation which comprises as an active ingredient 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4-(5H)-one or a pharmaceutically acceptable acid addition salt thereof in admixture with a pharmaceutically acceptable carrier.



KWK:0889y

Further, the present invention provides use of
2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)
ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one
or a pharmaceutically acceptable acid addition salt
5 thereof, for preparing an agent having a renal
function-improving effect and a diuretic effect.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

10 The above 8-chloro-benzothiazepine compound which is an
active ingredient of the present invention has excellent
renal function-improving activity and diuretic activity.

For example, in case where the 30 minutes clamping is
15 applied to the renal artery in the rats after
contralateral nephrectomy, they will suffer from an
ischemia-induced acute renal failure. Moreover, when
glycerol is intramuscularly administered to rats, they
will suffer from acute renal failure. In these cases,
20 values of urea nitrogen and creatinine in blood of the
rats will be abnormally increased as in the case of human
acute renal failure. The 8-chloro-benzothiazepine
compound which is the active ingredient of the present
invention exhibits an excellent effect that these values
25 are excellently improved. Also, when a stroke-prone
spontaneously hypertensive rat (SHRSP) is fed with a diet
containing sodium chloride, renal disorder (azotemia)
which is similar to chronic renal failure will be caused
and kidney lesions (e.g. atrophy of uriniferous tubules,
30 collapse or sclerosis of glomerular tufts) may be
observed. However, in cases where the 8-chloro-
benzothiazepine compound which is the active ingredient
of the present invention is administered, the compound
exhibits an excellent effect that such lesions in kidney
35 can be prevented. Accordingly, the pharmaceutical
preparation of the present invention having such effects
can be used for prophylactic and therapeutic agents for
renal failure.

Further, when the above 8-chloro-benzothiazepine compound which is the active ingredient of the present invention is orally administered to SHR (dose: 10 mg/kg), the compound exhibits an excellent effect such that urine
5 volume and amount of sodium ion and chloride ion excreted in the urine are increased by 70% or more, respectively, without affecting the excretion of potassium. Therefore, the pharmaceutical preparation of the present invention can be used for a diuretic agent which has no fear of
10 causing hypokalemia.

The agent having a renal function-improving effect and a diuretic effect of the present invention can be used by both oral and parenteral administration to a warm-blooded animal including a human being. When used orally, the 8-chloro-benzothiazepine compound or a pharmaceutically acceptable acid addition salt thereof can be used as such or in the form of pharmaceutical preparations suitable for oral administration with pharmaceutically acceptable carriers such as excipients,
20 binding agents, disintegrators and lubricants. The pharmaceutically acceptable carriers include, for example, starch, lactose, glucose, gelatin, sorbit, tragacanth, polyvinyl pyrrolidone, sugar, corn starch, polyethylene glycol, talc, potassium phosphate, magnesium stearate and other conventional excipients, binding agents, disintegrators and lubricants. The preparation for administration may be in solid form such as tablets, capsules, granules, microcapsules and suppositories, or in liquid form such as solutions, suspensions and
30 emulsions. For parenteral administration, the agent of the present invention may be suitably used in the form of injections. For the solvent for the injections, distilled water for injection, vegetable oil and propylene glycol can be used. Further, the injection may contain solubilizers, buffers and stabilizers.

The 8-chloro-benzothiazepine compound, which is an active ingredient of the present invention, can be used in the form of free base or a pharmaceutically acceptable acid addition salt thereof. The pharmaceutically acceptable acid addition salt can be, for example, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate and phosphate, or organic acid salts such as oxalate, maleate, fumarate, tartrate and methanesulfonate.

10

The dose of the agent of the present invention may vary depending on the disease condition, the age, body weight and severity of symptoms of the patient, administration route, etc., but the proper dose of the 8-chloro-benzothiazepine compound or a pharmaceutically acceptable acid addition salt thereof may be in the range of 0.05 to 100 mg/day/kg, preferably in the range of 0.1 to 30 mg/day/kg.

15

20

As mentioned above, since the agent of the present invention has an effect for improving the abnormality in concentrations of urea nitrogen and creatinine in blood under the state of renal failure, as well as it prevents the kidney lesions in the chronic renal failure, the agent can be used for the treatment and prophylaxis for acute and chronic renal failures resulting from various renal diseases such as glomerulonephritis, nephrotic syndrome, nephrosclerosis, tubular disorder and ischemic renal failure.

25

30

Further, since the agent of the present invention acts for increasing urine volume and amounts of sodium ion and chloride ion in the urine without affecting the excretion of potassium, it can be used for the treatment of symptoms of edema, renal failure, etc. as a diuretic agent which has no fear of causing hypokalemia.

35

Since the 8-chloro-benzothiazepine compound which is the active ingredient of the present invention has two asymmetric carbon atoms in the molecule, there exist two kinds of stereoisomers (namely, cis- and trans-isomers) or four kinds of optical isomers (namely, (+)-cis-, (-)-cis-, (+)-trans- and (-)-trans-isomers). For the object of the present invention, any of these isomers and mixtures thereof can be used, but in general it is preferable to use a cis-isomer.

Experimental example 1

(Effect on ischemic acute renal failure)

(+)-Cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate was used as the test compound.

Ischemic acute renal failure (ARF) was induced in male Sprague-Dauley rats (one group consisting of 11 rats) weighing 270 to 360 g. They were fasted overnight and anesthetized with pentobarbital Na (50 mg/kg i.p.). After right nephrectomy, the left renal artery was clamped for 30 minutes. An intravenous infusion of saline or the test compound solution was started in all animals 15 minutes before the initiation of clamping and was continued during the 30-minutes clamping period. The abdominal wall was closed and the rats were placed in individual cages. Urine was collected for 24 hours under free access to food and water. 24 Hours later, blood was drawn for analysis.

Three groups of rats studied were as follows:

- 1) Sham operated rats (sham)
- 2) Untreated control animals with ischemic ARF. (ARF control)

3) Ischemic ARF, treated by the intravenous infusion of the test compound at a rate of 20 µg/kg/min.

5 Plasma urea and creatinine, and urine creatinine, sodium, osmolarity and NAG (N-acetyl-β-D-Glucosaminidase) were determined by standard methods. Creatinine clearance, fractional excretion of sodium and NAG index were calculated with standard formulas.

10 (Results)

The results are shown in Table 1.

Table 1

Dose µg/kg/min.	PUN (mg/dl)	Pcr (mg/dl)	FENa (%)	Ccr (ml/24hr)	Uosm (mOsm /kg H ₂ O)	NAGindex (Unit of creati- nine)
Sham	23.2 ± 1.7	0.7 ± 0.04	0.54 ± 0.10	1589 ± 105	1286 ± 123	33.8 ± 5.6
ARF Control	101.0## ± 8.6	3.3## ± 0.4	9.67## ± 2.34	236## ± 78	598## ± 43	83.5## ± 7.5
20	63.7## ± 10.0*	1.7 ± 0.3*	2.90 ± 1.25	816## ± 170**	818## ± 74	66.6# ± 12.0

#P < 0.05, ##P < 0.01 vs Sham Group

*P < 0.05, **P < 0.01 vs ARF Control Group

PUN ; Plasma Urea Nitrogen Concentration

Pcr ; Plasma Creatinine Concentration

FENa; Fractional Excretion of Sodium

Ccr ; Creatinine Clearance

Uosm; Urine Osmolarity

NAGindex; N-Acetyl-β-D-Glucosaminidase index

As can be seen from Table 1, twenty-four hours after the ischemic insult, the untreated control rats caused marked increases in plasma urea (PUN) and creatinine (Pcr) levels and a significant decrease in creatinine clearance (Ccr) value. These rats also had higher fractional excretion of sodium (FENa) and NAG index, and lower urinary osmolarity (Uosm). Thus, the untreated control rats showed an acute renal failure (ARF).

ARF rats treated with the test compound (20 µg/kg/min) exhibited significantly lower PUN, Pcr, FENa and NAG index, and higher Ccr than those in the untreated control rats.

This means that the test compound is effective in reducing the severity of ischemic acute renal failure.

Experimental example 2

(Effect on glycerol-induced acute renal failure in rats)

SD strain male rats (age: 7 weeks; one group consisting of 4 to 5 rats) dehydrated for 24 hours were administered intramuscularly at femoral region with 50% glycerol-physiological saline at a dose of 10 ml/kg.

In order to examine the effect of the present pharmaceutical preparation on the acute renal failure induced under such experimental conditions, the test compound administration groups had been orally administered with an aqueous solution of (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate at a dose of 10 mg/kg and 30 mg/kg, respectively, at a prescribed time of the day for the three days before the administration of glycerol. After administration of the glycerol, the test compound was orally administered in the similar manner.

On the other hand, the control group was orally administered with water instead of the test compound solution.

5 After three days of the administration of the glycerol, celiotomy was conducted for each rat of the both groups under ether anesthesia, and blood was collected from the abdominal aorta. Then, serum separated from said blood
10 as subjected to a biochemical analysis.

(Result)

Results are shown in Table 2 below.

Table 2

	Test compound administration group (dose: mg/kg/day)		Control group
	10	30	
Serum urea nitrogen (mg/dl)	81.3 \pm 39.4	66.4 \pm 13.1	119.1 \pm 89.3
Serum creatinine (mg/dl)	1.68 \pm 0.68	1.28 \pm 0.14	3.37 \pm 1.41

15 From the above Table, it can be recognized that the concentrations of serum urea nitrogen and creatinine are remarkable increased in the control group with acute renal failure. However, in the test compound
20 administration group, the concentrations are lowered dose-dependently in both cases, and therefore it is apparent that the onset of acute renal failure are inhibited.

Experimental example 3

(Effect on chronic renal failure in rats)

5 Stroke-prone spontaneously hypertensive rats (SHRSP, age:
13 weeks, one group consisting of 8 rats) were fed with a
powder diet containing 8% sodium chloride for three
weeks. In order to examine the effect of the pharma-
10 ceutical preparation of the present invention on chronic
renal failure induced under such conditions, the test
compound administration group was fed with a powder diet
containing 8% sodium chloride and 1000 ppm of (+)-cis-2-
15 (4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-
chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate
for three weeks. On the other hand, the control group
was fed with a powder diet containing 8% sodium chloride
for 3 weeks.

20 After the feeding, celiotomy was conducted for each rat
under ether anesthesia, and blood was collected from the
abdominal aorta and then the rats were killed. The
collected blood was subjected to a biochemical analysis,
as well as the kidney was subjected to a histopatho-
logical examination.

25 (Result)

Results are shown in Table 3 below.

Table 3

	Test compound administration group	Control group
Atrophy of uriniferous tubule	Δ 0/8 \blacktriangle 0/8	Δ 2/8 \blacktriangle 5/8
Collapse or sclerosis of glomerular tuft	Δ 0/8 \blacktriangle 0/8	Δ 3/8 \blacktriangle 1/8
Proteinaceous casts	Δ 0/8 \blacktriangle 0/8	Δ 7/8 \blacktriangle 0/8
Serum creatinine (mg/dl)	$0.58 \pm 0.02^*$	0.68 ± 0.02

In the above Table, *, Δ and \blacktriangle mean the following, respectively.

*; $p < 0.01$

5

Atrophy of uriniferous tubule

10

Δ means the case where uriniferous tubule accompanied with epithelial cell with reduced staining properties, luminal constriction and winding basement membrane can be observed at the area of not less than 30% and less than 60 % on the cut surface of kidney.

15

\blacktriangle means the case where the above changes are observed at the area of 60% or more on the cut surface of kidney.

Collapse or sclerosis of glomerular tuft

5 △ means that collapse or sclerosis of glomerular tufts are observed in 30% or more and less than 60% of the total glomeruli on the cut surface.

 ▲ means the above changes are observed in 60% or more of the total glomeruli on the cut surface.

10 Proteinaceous cast

 △ means that the proteinaceous casts are scattered at cortical part.

15 ▲ means that the proteinaceous casts are observed extensively at cortical part.

From Table 3, in the control group, histopathological changes such as atrophy of uriniferous tubule, collapse or sclerosis of glomerular tuft and proteinaceous casts which mean the presence of proteinuria, are remarkable. On the contrary, in the test compound administration group, it is apparent that such renal lesions are not recognized.

25 Also, in the control group, due to the fact that the serum creatinine is increased, it can be seen that rats of the control group are clinically suffered from renal failure. However, in the test compound administration group, such phenomena are not observed at all.

Experimental example 4

(Effect on electrolyte balance and urine volume)

35 Groups of 10 male SHR weighing 335 to 415 g were fasted overnight and then orally administered with 2.5 ml/100 g

of physiological saline. One hour later, the rats were given (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate dissolved in physiological saline at prescribed concentrations. Rats of the control group were given orally 2.5 ml/100 g of physiological saline instead of the test compound solution. Immediately afterwards, the animals were individually housed in a metabolic cage for 5 hr. The urine excreted during this period was collected and its volume was measured. The concentrations of electrolytes (sodium, potassium and chloride ions) in the urine were determined and the amounts excreted were calculated.

15 (Results)

The results are shown in Table 4.

Table 4

Dose mg/kg	Urine volume ml/100g/5hr	Excretion of chloride $\mu\text{gEq}/100\text{g}/5\text{hr}$	Excretion of sodium $\mu\text{gEq}/100\text{g}/5\text{hr}$	Excretion of potassium $\mu\text{gEc}/100\text{g}/5\text{hr}$	Sodium/Potassium ratio in urine
(Control)	1.75+0.69	298+25	258+22	65+7	4.11+0.37
3	2.14+0.95	359+47	327+40	63+9	5.36+0.34
10	3.02+0.15*	527+24*	505+24*	68+7	7.74+0.56*

* : $P < 0.01$

As clearly shown in Table 4, the 8-chloro-benzothiazepine compound, which is an active ingredient of the present invention at the dose of 10 mg/kg increased the urine volume by 73% and the excretion of sodium and chloride ions by 96 and 77%, respectively, in comparison with those of the control group. However, the compound did not affect the excretion of potassium ion and therefore significantly increased the sodium/potassium ratio in the urine.

10

Example 1

(Tablet)

15

(+)-Cis-8-chloro-benzothiazepine compound

(maleate) 45.0 g

Corn starch 20.1 g

20

Lactose 82.4 g

Polyvinyl pyrrolidone 3.0 g

25

Crystalline cellulose 38.0 g

Magnesium stearate 1.5 g

30

Total 190.0 g

35

The (+)-cis-8-chlorobenzothiazepine compound (maleate), lactose and corn starch were mixed with an alcohol solution of polyvinyl pyrrolidone and granulated by kneading according to the wet granulation method, followed by drying to be formed into granules.

Subsequently, magnesium stearate and crystalline cellulose were added to the granules and the mixture is compressed by a tableting machine to give tablets of 8 mm in diameter and 190 mg in weight.

5

Example 2

(Injection)

10 Ten grams of (+)-cis-8-chlorobenzothiazepine compound
(maleate) were dissolved in 2 liter of distilled water
for injection. The solution was filtered through a
membrane filter with a pore size of 0.22 µm, and was
poured into ampoules under aseptic conditions each in 2
15 ml and sealed to give ampoules for injection.

Example 3

(Powders)

20

(+)-Cis-8-chlorobenzothiazepine compound

(maleate) 10 g

25

Lactose 90 g

Total 100 g

30 The above-mentioned ingredients were homogeneously mixed
in a double conical mixer to give 10-fold trituration.

The claims defining the invention are as follows:

1. A method for the treatment or prophylaxis of renal failure or edema in a patient requiring said treatment or prophylaxis, which method comprises administering to said patient an effective renal function improving or diuresis inducing amount of a formulation which comprises as an active ingredient 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)-ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4-(5H)-one or a pharmaceutically acceptable acid addition salt thereof in admixture with a pharmaceutically acceptable carrier.

2. The method according to Claim 1, wherein said active ingredient is (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one or a pharmaceutically acceptable acid addition salt thereof.

3. The method according to Claim 1 or Claim 2 wherein said pharmaceutically acceptable acid addition salt is one selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, phosphate, oxalate, maleate, fumarate, tartarate and methanesulfonate.

4. The method according to Claim 3 wherein said pharmaceutically acceptable acid addition salt is maleate.

5. A method according to any one of claims 1 to 4 wherein the renal failure is acute or chronic renal failure resulting from glomerulonephritis, nephrotic syndrome, nephrosclerosis, tubular disorder or ischemic renal failure.

6. A formulation whenever used with the method of any one of claims 1 to 5 which comprises as an active ingredient 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4-(5H)-one in admixture with a pharmaceutically acceptable carrier.

7. A method for the treatment or prophylaxis of renal failure or edema demonstrated in a patient requiring said treatment or prophylaxis, which method comprises administering to said patient an effective renal function improving or diuresis inducing amount of a formulation which comprises as an active ingredient 2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethyl-amino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4-(5H)-one, said formulation being substantially as hereinbefore described with reference to any one of Examples 1 to 3.



